Journal
LEUKEMIA RESEARCH
Volume 39, Issue 2, Pages 216-220Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2014.08.016
Keywords
Decitabine; Resistance; hENT1 gene; DCK gene
Categories
Funding
- National Public Health Grand Research Foundation [201202017]
- National Natural Science Foundation of China [81270648]
- Guangdong Province Science Foundation of China [S2012010009560]
Ask authors/readers for more resources
Decitabine is approved for the treatment of MDS, but resistance to this agent is common. To determine the mechanisms underlying decitabine resistance, we measured the mRNA expression of metabolism (hENT1, DCK, CDA) and apoptosis (BCL2L10) genes and found that the hENT1 mRNA level was significantly higher in response compared with non-response patients (P=0.004). Furthermore, the DCK level was significantly reduced for relapse (P=0.012) compared with those with continued marrow CR (P=0.222). These findings indicate that the decitabine metabolic pathway affects its therapeutic effects, lower hENT1 expression may induce primary resistance and down-regulated DCK expression may be related to secondary resistance. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available